IP Library Granted Patent US 10,006,079
Granted Patent B2
US 10,006,079 · App. 14/294,547 · Granted Jun 26, 2018

Method for establishing the anti-diabetic potential of bitter melon

Inventors: Dallas L. Clouatre (Seattle, WA); Daniel E. Clouatre (Seattle, WA)
Assignee: Glykon Technologies Group, LLC
C12Q1/54G01N2333/39
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,006,079
App. No.
14/294,547
Granted
Jun 26, 2018
Kind
B2
Abstract

A method is disclosed for determining the hypoglycemic potential of Momordica charantia (bitter melon) extracts through an in vitro test representative of the range of serum blood sugar typical of normal and diabetic subjects. The in vitro assay provides information on the functional activity of bitter melon extracts for regulating blood glucose uptake in an animal or human.

Claims (20)

1. An in vitro assay method, comprising:

(a) adding to a closed environment yeast cells a known amount of glucose to obtain a known concentration of glucose;

(b) adding a known amount of extract of Momordica charantia obtained from a first batch of Momordica charantia to the closed environment of yeast cells to provide a known concentration of the extract of Momordica charantia in the closed environment;

(c) waiting a period of time after adding the extract of Momordica charantia for glucose uptake by the yeast cells;

(d) determining a second glucose concentration in the closed environment of yeast cells;

(e) comparing the known glucose concentration in step (a) to the second glucose concentration in step (d);

(f) determining a differential between the known glucose concentration and the second glucose concentration for the first batch of Momordica charantia ; and

(g) repeating steps (a)-(f) with a second batch of extract of Momordica charantia thereby determining a second differential for the second batch of extract of Momordica charantia , and comparing the differential determined for each batch to a known standard thereby determining the hypoglycemic potential of the extract of Momordica charantia.

2. The method of claim 1 , further comprising: using the differential determined in step (g) for each batch to optimize dosing of a subject with the extract of Momordica charantia.

3. The method of claim 1 , further comprising:

using the differential to optimize dosing of a subject with the extract.

4. The method of claim 1 , further comprising: repeating steps (a)-(f) a plurality of times with extracts obtained from different batches of Momordica charantia to make a batch-by-batch comparison of the differential determined for each batch to optimize dosing of a subject with the extract of Momordica charantia.

5. An in vitro assay method, comprising:

(a) adding to a closed environment of yeast cells a known amount of glucose to obtain a known concentration of glucose;

(b) adding a known amount of extract of Momordica charantia obtained from a first batch of Momordica charantia to the closed environment of yeast cells to provide a known concentration of the extract of Momordica charantia in the closed environment;

(c) waiting a period of time after adding the extract of Momordica charantia for glucose uptake by the yeast cells;

(d) determining a second glucose concentration in the closed environment of yeast cells;

(e) comparing the known glucose concentration in step (a) to the second glucose concentration in step (d);

(f) determining a differential between the known glucose concentration and the second glucose concentration for the first batch of extract of Momordica charantia;

(g) repeating steps (a)-(f) a plurality of times with extract obtained from different batches of Momordica charantia to make a batch-by-batch comparison of the differential determined from each batch; and using the differential to optimize dosing of a subject with the extract of Momordica charantia.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 3, 2026
From: NUTRITION RESEARCH GROUP, LLC
To: CLOUATRE, DANIEL E.
Reel/Frame 073675/0820 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 3, 2026
From: CLOUATRE, DANIEL E.
To: HEALTHTAKE CORPORATION
Reel/Frame 073675/0823 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 5, 2022
From: GLYKON TECHNOLOGIES GROUP, LLC
To: NUTRITION RESEARCH GROUP, LIMITED
Reel/Frame 058559/0645 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 2, 2014
From: CLOUATRE, DALLAS L.; CLOUATRE, DANIEL E.
To: GLYKON TECHNOLOGIES GROUP, LLC
Reel/Frame 033230/0653 →
Continuity (2)
Provisional Application 61963511 · Dec 4, 2013
Related Publication 20150125887A1 · May 7, 2015